SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin getting ready for next wave of growth in Japan: Report

26 Jun 2018 Evaluate

Lupin is reportedly getting ready for the next wave of growth in Japan which will come from biosimilars. The Mumbai-based pharmaceutical company expects 50% of Japan sales to come from the speciality business.

The company has achieved a 23.4% of year on year (YoY) growth rate in Japan sales in Financial Year 2018 which is highest in past five year.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2457.45 -32.40 (-1.30%)
08-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1887.95
Dr. Reddys Labs. 1348.70
Cipla 1431.65
Zydus Lifesciences 1149.00
Lupin 2457.45
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: